Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study
Year: 2018
Type: article
Abstract: Background: For pts with unresectable HCC, systemic therapy options are limited. Sorafenib and lenvatinib are approved in the US and Europe for HCC treatment. For pts who progress on sorafenib, regorafenib and nivolumab are approved as second-line therapy. Cemiplimab (REGN2810) has demonstrated encouraging efficacy and safety profile in a Phase 1 dose escalation study in pts with advanced malignancies (NCT02383212). We present results of the Phase 1 HCC EC.
Source: Annals of Oncology
Institutions: Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, University of Arizona College of Medicine- Phoenix, HealthONE, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Hospital Universitario Fundación Jiménez Díaz, Vall d'Hebron Hospital Universitari, Providence Portland Medical Center, Oregon Clinic, Weill Cornell Medicine, University of Kansas, The University of Kansas Cancer Center, South Texas Accelerated Research Therapeutics, Regeneron (United States)
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W4242043766